Cytotoxic T-lymphocyte Antigen-4 (CTLA-4) Gene Polymorphism (rs3087243) Is Related to Risk and Survival in Patients With Colorectal CancerShow others and affiliations
2021 (English)In: In Vivo, ISSN 0258-851X, E-ISSN 1791-7549, Vol. 35, no 2, p. 969-975Article in journal (Refereed) Published
Abstract [en]
Background/Aim: Cytotoxic T-lymphocyte antigen 4 (CTLA-4), transiently expressed on T cells, plays a pivotal role in the negative feedback regulation of T-cell activation and proliferation. The aim of the present study was to examine the influence of CTLA-4 gene polymorphism rs3087243 on CRC susceptibility and long-term survival in Swedish patients with CRC. Patients and Methods: Genotypes of 491 patients and 433 healthy controls were determined, using TaqMan single nucleotide polymorphism (SNP) assays based on polymerase chain reaction. Results: Patients carrying allele A were found to be at a higher risk of CRC and this allele was found to be more common in patients with disseminated disease compared to localized disease in the right colon. Kaplan-Meier analysis of cancer-specific survival showed that carriers of allele A had the highest risk of CRC-related death. Conclusion: The SNP rs3087243 of the CTLA-4 gene was associated with CRC risk and, therefore, it could be a prognostic marker for Swedish patients with CRC.
Place, publisher, year, edition, pages
INT INST ANTICANCER RESEARCH , 2021. Vol. 35, no 2, p. 969-975
Keywords [en]
CTLA-4; SNP; colorectal cancer
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-176001DOI: 10.21873/invivo.12339ISI: 000648906100005PubMedID: 33622891OAI: oai:DiVA.org:liu-176001DiVA, id: diva2:1559311
Note
Funding Agencies|Medical Research Council of Southeast SwedenUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Division of Medical Diagnostics, Region Jonkoping County, Sweden
2021-06-022021-06-022021-12-29